Results 91 to 100 of about 11,301 (165)

Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome

Инновационная медицина Кубани
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme involved in the regulation of blood cholesterol levels by binding to low-density lipoprotein receptors and promoting their degradation. Pivotal studies have shown that PCSK9 inhibition by
A. M. Namitokov, V. K. Zafiraki, K. V. Karabakhtsieva   +2 more
doaj   +1 more source

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors

Global Cardiology Science and Practice, 2017
[first paragraph of article]The 2003 discovery of proprotein convertase subtilisin–kexin type-9 (PCSK9) – a circulating protein targeting the low density lipoprotein (LDL) receptor for its degradation – paved the way for the development of several therapeutic approaches which inhibit the protein itself (by monoclonal antibodies) or its RNA (by RNA ...
openaire   +3 more sources

Application of a PCSK9 inhibitor in the treatment of lipid disorders – a comprehensive literature

Quality in Sport
Lipid disorders stem from imbalances in the levels of cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL), and triglycerides (TG).
Piotr Rzyczniok, Aneta Rasińska, Weronika Rasińska, Anna Rzyczniok, Justyna Matusik, Natalia Pasierb, Sebastian Kupisiak, Aneta Rostkowska, Paulina Bala, Anna Rebizak, Justyna Jachimczak   +10 more
doaj   +1 more source

Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis

BMC Cardiovascular Disorders
Background Acute coronary syndrome (ACS) remains a leading cause of global cardiovascular morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a key modifiable risk factor. Despite statin therapy, many patients fail to
Guoying Kao, Chuan Chen, Ying Zhang, Yi Xu, Gang Xu   +4 more
doaj   +1 more source

Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis

International Journal for Equity in Health
Background PCSK9 inhibitors are a novel class of lipid-lowering drugs that have demonstrated favorable efficacy and safety. Evolocumab and alirocumab have been added to China’s National Reimbursement Drug List through the National Drug Price Negotiation (
Lingli Zhang, Xiaoye Wang, Hongting Yao, Baolong Ding, Xingyuan Gao, Xin Li   +5 more
doaj   +1 more source

A register-based cohort study on the effectiveness and Safety of anti-PCSK9 treatment in persons with hyperlipidemia

Communications Medicine
Background Dyslipidemia is a known risk factor for cardiovascular disease. While statins are the primary treatment, some individuals require additional lipid-lowering therapies, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors ...
Michael Asger Andersen, Anne Helms Andreasen, Lia Evi Bang, Espen Jimenez-Solem, Tonny Studsgaard Petersen   +4 more
doaj   +1 more source

PCSK9 Inhibitors Prior Authorization [PDF]

Circulation: Cardiovascular Quality and Outcomes, 2019
Khurram Nasir, Suveen Angraal, Salim S. Virani   +2 more
openaire   +1 more source

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab

Vascular Health and Risk Management, 2016
Dirk J Blom,1 Ricardo Dent,2 Rita C Castro,2 Peter P Toth3,4 1Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa; 2Amgen, Inc., Thousand Oaks, CA, 3Ciccarone Center for the Prevention of Cardiovascular ...
Blom DJ, Dent R, Castro RC, Toth PP
doaj  

PCSK9 inhibitors: a promising lipid-lowering strategy for kidney transplant recipients. [PDF]

Ren Fail
Luo B, Guo L, Di W.
europepmc   +1 more source

Association of PCSK9 inhibitors versus statins with cancer incidence: a target trial emulation. [PDF]

Cardiooncology
Huang CH, Wang SI, Fan FS, Lu HJ, Wei JC.   +4 more
europepmc   +1 more source